Five facility certificates published
Certification Assurance International issued Lyotek Labs five facility certificates on 27 October 2026, and all of them are now published on this site as the issuer's PDFs.
All press releases
Retatrutide joins the catalogue in 20 mg and 40 mg vials
Lyotek adds retatrutide to its metabolic research range, in two presentations of the same 3 ml vial.
Retatrutide joins tirzepatide and MOTS-c in the metabolic range of the Lyotek catalogue.
Offering two strengths lets a laboratory choose the quantity that suits its work without combining vials. Both are lyophilised and filled into the same 3 ml vial, with the strength printed on the label.
Retatrutide is supplied for research use only, with a certificate of analysis for every lot.
Lyotek products are supplied for research use only.
More from the laboratory
Lyotek research peptides now reach more than 170 countries
Through its exclusive distributor, Lyotek research peptides now reach laboratories in more than 170 countries from the laboratory in Switzerland.
Our exclusive distributor expands to the Middle East, Southeast Asia and Latin America
Lyotek's exclusive distributor has extended its coverage to three new regions, which brings local support to laboratories there.